Growth Metrics

KalVista Pharmaceuticals (KALV) Net Margin (2014 - 2025)

KalVista Pharmaceuticals recorded quarterly Net Margin of 105.51% in Q3 2025, down 129.45% quarter-over-quarter from 358.27% in Q2 2025.

KalVista Pharmaceuticals' Net Margin history runs 8 years deep, the most recent figure standing at 105.51% for Q3 2025.

  • In Q3 2025, Net Margin changed N/A year-over-year to 105.51%; the TTM figure through Jul 2025 stood at 90.75% (up 65066.0% YoY), while the FY2025 annual figure was 834.62%, down 72930.0% from the prior year.
  • Net Margin came in at 105.51% for Q3 2025 at KalVista Pharmaceuticals, down from 358.27% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 358.27% in Q2 2025 to a low of 105.51% in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 0.82%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 34.53%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 20.17%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 17.65%
10 KalVista Pharmaceuticals 1.44 Bn 1.25 Bn 56.41 Mn -105.51%

Historic Data

Download Data 🔒
DateValue
Jul 31, 2025 -105.51%
Apr 30, 2025 358.27%
Apr 30, 2020 -224.74%
Jan 31, 2020 -783.26%
Oct 31, 2019 -224.08%
Jul 31, 2019 -266.37%
Apr 30, 2019 -371.80%
Jan 31, 2019 -152.62%
Oct 31, 2018 -83.85%
Jul 31, 2018 -186.12%
Apr 30, 2018 -13.57%
Jan 31, 2018 -224.54%
Oct 31, 2017 -442.41%
Jul 31, 2017 -5,133.33%
Apr 30, 2017 -3,685.96%
Jan 31, 2017 -3,167.34%
Oct 31, 2016 -2,152.79%
Jul 31, 2016 -458.97%
Mar 31, 2016 -94,342.86%
Dec 31, 2015 -80,800.00%
Sep 30, 2015 -71,314.29%
Jun 30, 2015 -83,342.86%
Mar 31, 2015 -74,057.14%
Sep 30, 2014 -39,240.00%
Jun 30, 2014 -50,360.00%
Mar 31, 2014 -33,583.33%